Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis

Virology Journal, Год журнала: 2024, Номер 21(1)

Опубликована: Фев. 23, 2024

Abstract Background Azvudine has been approved for the treatment of coronavirus disease 2019 (COVID-19) patients in China, and this meta-analysis aims to illustrate safety azvudine its effectiveness reducing mortality. Methods PubMed, Embase, Web science, Cochrane Library Epistemonikos COVID-19 Living Overview Evidence database (L.OVE) were searched aggregate currently published studies. risk bias tool ROBINS-I used assess randomized controlled study cohort respectively. Odds radios (ORs) with 95% confidence interval (CIs) combined dichotomous variables. Publication was assessed by Egger’s test funnel plots. Results A total 184 articles retrieved from included databases 17 studies into final analysis. Pooled analysis showed that significantly reduced mortality compared controls (OR: 0.41, 95%CI 0.31–0.54, p < 0.001). Besides, either mild moderate or severe could benefit administration. There no significant difference incidence ICU admission 0.90, 0.47–1.72, = 0.74) invasive ventilation 0.94, 0.54–1.62, 0.82) between control group. The adverse events similar 1.26, 0.59–2.70, 0.56). Conclusions This suggests reduce patients, administration is acceptable. Trial registration PROSPERO; No.: CRD42023462988; URL: https://www.crd.york.ac.uk/prospero/ .

Язык: Английский

---

Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Янв. 16, 2025

Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. However, efficacy safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalized from eleven hospitals Henan Xinjiang Provinces, China. Clinical outcomes compared between two drugs via Kaplan-Meier analysis Cox regression models. Additionally, vitro vivo experiments evaluate antitumor effects both drugs. Single-cell RNA sequencing was performed elucidate tumor immune landscape after treatment. After propensity score matching, 2404 1202 recipients Province included. revealed that related an 18% lower risk all-cause death than (95% CI: 0.676-0.987), not obviously different composite disease progression. The robustness findings verified by cohort three sensitivity analyses. Fewer adverse events observed group. Subgroup provided greater benefits for malignant tumors, significantly reducing (hazard ratio [HR]: 0.33, 95% 0.20-0.54) progression (HR: 0.54, 0.33-0.88). Furthermore, can suppress growth hepatocellular carcinoma (HCC) regulating CD4+ T CD8+ cells vivo. These suggest therapy is inferior has fewer effects. Notably, may offer clinical benefit HCC.

Язык: Английский

---

Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study

Acta Pharmaceutica Sinica B, Год журнала: 2023, Номер 13(11), С. 4655 - 4660

Опубликована: Июль 13, 2023

In our retrospective cohort study, we aim to explore whether Azvudine modifies the risk of death in COVID-19 patients. It was conducted on medical records patients, consecutively admitted for pneumonia two hospitals Chongqing, China. Based treatment exposure, patients were divided into group and non-Azvudine group. We used 1:2 ratio propensity score matching (PSM) study adjust confounding factors differences between groups. There 1072 included original cohort. With PSM, 195 390 The results showed that associated with improved in-hospital mortality overall population (OR 0.375, 95% CI 0.225-0.623, P < 0.001), severe subgroup 0.239, 0.107-0.535, = critical 0.091, 0.011-0.769, 0.028) matched univariate analysis. And there a significantly lower (11% vs. 24%, P＜0.001), sub-group (10% 32%, 0.001) (5% 34%, 0.017) These suggest can reduce severe, population.

Язык: Английский

---

COVID-19 drugs: a critical review of physicochemical properties and removal methods in water

Journal of environmental chemical engineering, Год журнала: 2025, Номер 13(1), С. 115310 - 115310

Опубликована: Янв. 5, 2025

Язык: Английский

---

Azvudine versus Paxlovid in COVID‐19: A systematic review and meta‐analysis

Reviews in Medical Virology, Год журнала: 2024, Номер 34(4)

Опубликована: Июнь 7, 2024

Abstract This systematic review and meta‐analysis aimed to compare the effectiveness safety of azvudine versus nirmatrelvir/ritonavir (Paxlovid) in treating coronavirus disease 2019 (COVID‐19). The researchers conducted searches on PubMed, Cochrane Library, Web Science, medRxiv, Google Scholar until January 2024. risk bias tool was utilised evaluate quality included studies, data analysis performed using Comprehensive Meta‐Analysis software. Thirteen including 4949 patients, were analysed. results showed no significant difference between Paxlovid groups terms mortality rate (odds [OR] = 0.84, 95% confidence interval [CI]: 0.59–1.21), negative polymerase chain reaction (PCR) conversion time (standard mean [SMD] 1.52, CI: −1.07–4.11), hospital stay (SMD −0.39, −1.12–0.33). However, a observed two intensive care unit admission (OR 0.42, 0.23–0.75) need for mechanical ventilation 0.61, 0.44–0.86) favour azvudine. incidence adverse events group significantly lower 0.66, 0.43–0.99). certainty evidence rated as low moderate. Azvudine demonstrated similar reducing rates, PCR stay. better improving other outcomes. Regarding level evidence, further research is needed validate or challenge these results.

Язык: Английский

---

Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience

Advanced Science, Год журнала: 2024, Номер 11(23)

Опубликована: Март 27, 2024

Abstract COVID‐19 can lead to adverse outcomes in patients with pre‐existing diseases. Azvudine has been approved for treating China, but the real‐world data is limited. It aimed investigate efficacy of and cardiovascular Patients confirmed diseases are retrospectively enrolled. The primary outcome all‐cause death during hospitalization. Overall, 351 included, a median age 74 years, 44% female. 212 (60.6%) severe cases. used 106 (30.2%) not 245 (69.8%). 72 died After multivariate adjustment, who received lower risk (hazard ratio: 0.431; 95% confidence interval: 0.252–0.738; p = 0.002) than controls. therapy also associated risks shock acute kidney injury. For sensitivity analysis propensity score‐matched cohort ( n 90 each group), there significant difference between two groups 0.189; 0.071–0.498; < 0.001). This study indicated that better

Язык: Английский

---

Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study

View, Год журнала: 2025, Номер unknown

Опубликована: Фев. 5, 2025

Abstract Although azvudine has become a priority in the treatment of SARS‐CoV‐2, its effectiveness and safety among COVID‐19 patients who already have chronic respiratory diseases (CRDs) not been sufficiently validated. A retrospective, multicenter cohort study involving 10 hospitals Henan Province was performed to assess inpatients with CRDs (Clinical Trial Registration Number: NCT06349655). Azvudine recipients control group were matched at 1:1 ratio using propensity scores. The clinical outcomes (all‐cause death composite disease progression) analyzed Kaplan‒Meier Cox regression analyses, additional subgroup sensitivity analyses performed. Eighteen features included construct nomogram for predicting survival CRDs. Out 37,606 hospitalized patients, 1462 controls analysis. results multivariate demonstrated that contrast controls, use associated decreased risk all‐cause pre‐existing (log‐rank: p = .012; HR: 0.73; 95% CI: 0.553‒0.956); but significantly different terms progression .82; 1.15; 0.948‒1.383). An analysis subgroups three appraisals validate above outcomes. number type adverse events acceptable. concordance index (0.8499, 0.8497) area under curve (86.1%, 80.4%) showed satisfactory discriminative ability training test sets. could be effective reducing had few serious events.

Язык: Английский

---

Development and validation of a nomogram to assess the occurrence of liver dysfunction in patients with COVID-19 pneumonia in the ICU

BMC Infectious Diseases, Год журнала: 2025, Номер 25(1)

Опубликована: Март 10, 2025

The global pandemic of novel coronavirus pneumonia (COVID-19) has resulted in millions deaths over the past three years. As one most commonly affected extra-pulmonary organs, numerous studies have reported varying degrees liver injury a significant proportion patients with COVID-19, particularly severe and critically ill patients. Early prediction dysfunction hospitalized would facilitate clinical management COVID-19 improve prognosis, but reliable valid predictive models are still lacking. Methods We collected data from 286 RT-PCR confirmed admitted to various ICUs case system. These were randomly divided into training cohort (50%) validation (50%). In cohort, we first used ROC curves measure efficiency each variables for development damage during hospitalization followed by LASSO regression analysis screen logistic identify relevant risk factors. A nomogram based on these was created following above model. Finally, cohorts assessed using AUC, consistency index (C index), calibration Decision Curve Analysis. Results Out total 80 parameters ICUs, 10 determined be significantly associated occurrence hospitalization. Based predictors, further construct develop that offered practical application. C-index column line graphs 0.956 0.844 respectively. addition, model showed high degree agreement between predicted actual incidence COVID-19. Conclusion By developing nomogram, ICU. model's performance both cohorts, contributing

Язык: Английский

---

Advances in the effectiveness and safety of azvudine treatment: a comprehensive review

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 25, 2025

The global impact of COVID-19 has highlighted the urgent need for effective therapeutic interventions against SARS-CoV-2. Azvudine, a dual-target nucleoside drug initially developed human immunodeficiency virus (HIV), gained attention its potential in treating COVID-19. On 25 July 2022, Azvudine received conditional approval from National Medical Products Administration (NMPA) China, making it first oral SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor treatment. This review explores pharmacological activity, antiviral mechanisms, and clinical effectiveness azvudine context Clinical trials have demonstrated ability to reduce viral load, shorten time nucleic acid negativity, improve outcomes patients. Additionally, shown excellent pharmacokinetic properties favorable safety profile with mild side effects. also addresses importance interactions considerations, particularly high-risk populations. Research should focus on optimizing second-generation inhibitors enhanced variants, improving bioavailability, minimizing adverse effects, ensuring more robust treatment options

Язык: Английский

---

Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19

BMC Infectious Diseases, Год журнала: 2025, Номер 25(1)

Опубликована: Май 14, 2025

Язык: Английский

---